Stockscreener 앱 받기
8.66
7.71%
0.62
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - MarketBeat
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - StockTitan
(ALGS) Investment Analysis and Advice - Stock Traders Daily
Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com
Aligos Therapeutics names new chief medical officer By Investing.com - Investing.com Canada
Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Canada
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aligos Therapeutics names new chief medical officer - Investing.com
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - StockTitan
Aligos Therapeutics stock hits 52-week low at $8.5 - Investing.com
Aligos Therapeutics stock hits 52-week low at $8.5 By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - Defense World
Aligos Therapeutics' (ALGS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World
Market Recap Check: Aligos Therapeutics Inc (ALGS)’s Negative Finish at 10.18, Up/Down -28.11 - The Dwinnex
Aligos Phase II results for ALG-055009 in MASH fail to impress - The Pharma Letter
Aligos shares maintain Buy rating with price target after study - Investing.com
Aligos reports positive data from Phase IIa MASH treatment trial - Clinical Trials Arena
Aligos reports progress in MASH treatment study - Investing.com
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - Markets Insider
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - MarketBeat
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - ForexTV.com
Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear - Scrip
How will Aligos Therapeutics Inc’s (ALGS) earnings compare to estimates this quarter? - US Post News
Hark, Herald MASH phase II positive but Aligos THRown for a loop - BioWorld Online
Aligos reports progress in MASH treatment study - Investing.com India
Aligos stock falls on data for MASH candidate (NASDAQ:ALGS) - Seeking Alpha
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - 新浪香港
Aligos' fatty liver disease treatment meets main goal in mid-stage study - Reuters
Aligos Therapeutics Announces Positive Topline Results from - GlobeNewswire
Aligos Therapeutics Inc. (ALGS) Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - StreetInsider.com
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - StockTitan
Aligos Therapeutics to unveil Phase 2a study results By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Trading 3.5% Higher - MarketBeat
Aligos Therapeutics to unveil Phase 2a study results - Investing.com
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - ForexTV.com
Aligos Therapeutics to unveil Phase 2a study results By Investing.com - Investing.com UK
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - StockTitan
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 3.5% - Defense World
Zura Bio (NASDAQ:ZURA) versus Aligos Therapeutics (NASDAQ:ALGS) Critical Comparison - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 18.3% in August - Defense World
Liver Diseases Therapeutics Market Outlook Through 2024-2033 - WhaTech
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 18.3% in August - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 12.3% - MarketBeat
Piper Sandler keeps Aligos shares at Overweight rating with consistent price target - Investing.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $13.79 - MarketBeat
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? - MSN
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? - Yahoo Finance
Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance - BP Journal
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $11.94 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $11.94 - MarketBeat
Aligos Therapeutics regains Nasdaq compliance - Investing.com India
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN
Aligos Therapeutics regains Nasdaq compliance - Investing.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $13.16 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $13.16 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Decrease in Short Interest - Defense World
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Decreases By 95.5% - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase - Defense World
Brokers Offer Predictions for Aligos Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ALGS) - MarketBeat
Aligos Therapeutics (STU:5WK0) Cash Flow from Operations : €-78.87 Mil (TTM As of Jun. 2024) - GuruFocus.com
0.05%
4.86%
자본화:
|
볼륨(24시간):